| Zacks Company Profile for Alector, Inc. (ALEC : NSDQ) |
|
|
| |
| • Company Description |
| Alector Inc. is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Its product portfolio includes AL001, AL101, Al002 and AL003 which are in clinical stage. Alector Inc. is headquartered in South San Francisco, California.
Number of Employees: 238 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $1.55 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 4,935,299 shares |
| Shares Outstanding: 101.21 (millions) |
| Market Capitalization: $156.88 (millions) |
| Beta: 0.99 |
| 52 Week High: $6.14 |
| 52 Week Low: $0.87 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-48.33% |
-49.68% |
| 12 Week |
8.39% |
-0.19% |
| Year To Date |
-17.99% |
-30.00% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
131 OYSTER POINT BLVD. SUITE 600
-
SOUTH SAN FRANCISCO,CA 94080
USA |
ph: 415-231-5660
fax: - |
ir@alector.com |
http://www.alector.com |
|
|
| |
| • General Corporate Information |
Officers
Arnon Rosenthal - Co-founder and Chief Executive Officer
Louis J. Lavigne, Jr. - Chairperson
Marc Grasso - Chief Financial Officer
Elizabeth Garofalo - Director
Paula Hammond - Director
|
|
Peer Information
Alector, Inc. (CORR.)
Alector, Inc. (RSPI)
Alector, Inc. (CGXP)
Alector, Inc. (BGEN)
Alector, Inc. (GTBP)
Alector, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 014442107
SIC: 2836
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/25
Next Expected EPS Date: 11/05/25
|
|
Share - Related Items
Shares Outstanding: 101.21
Most Recent Split Date: (:1)
Beta: 0.99
Market Capitalization: $156.88 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.41 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-1.57 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 7.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 11/05/25 |
|
|
|
| |
